Itolizumab as the First Line of Treatment in Moderate to Severe Chronic Plaque Psoriasis- A Case Report

Authors

  • Shrilata S. Trasi
  • Nithin Sashidharan

Abstract

Abstract

Psoriasis is a chronic, autoimmune disease with a genetic predisposition. Among the various therapeutic options, biological therapies are emerging as a novel therapy in the management of this disease. Here, we present a case report of a patient who received Itolizumab as the first line of therapy.

Keywords: Psoriasis, Biologic, Itolizumab

Downloads

Download data is not yet available.

Published

01-03-2016

How to Cite

Trasi, S. S., and N. Sashidharan. “Itolizumab As the First Line of Treatment in Moderate to Severe Chronic Plaque Psoriasis- A Case Report”. Asian Journal of Pharmaceutical and Clinical Research, vol. 9, no. 2, Mar. 2016, p. 12, https://mail.innovareacademics.in/journals/index.php/ajpcr/article/view/10418.

Issue

Vol 9 Issue 2 (March-April) 2016

Section

Case Study(s)

The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.